Coherus Biosciences Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
CHRS Nasdaq 2833 https://www.coherus.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coherus Biosciences Inc

Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors - May 11th, 2022 10:00 pm
Shareholders in Coherus BioSciences (NASDAQ:CHRS) have lost 61%, as stock drops 12% this past week - May 11th, 2022 1:47 pm
Coherus BioSciences Management to Present at Upcoming Investor Conferences - May 10th, 2022 12:45 pm
Coherus BioSciences (CHRS) Q1 2022 Earnings Call Transcript - May 7th, 2022 5:30 am
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2022 9:35 pm
Coherus BioSciences Reports First Quarter 2022 Results - May 5th, 2022 8:01 pm
Coherus BioSciences Appoints Charlie Newton to Board of Directors - May 5th, 2022 12:31 pm
Coherus BioSciences Announces New Employment Inducement Grants - May 4th, 2022 1:45 am
FDA rejects Peninsula biotech's cancer drug — at least for now - May 2nd, 2022 8:09 pm
FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer - May 2nd, 2022 1:22 pm
Coherus, Shanghai Junshi get complete response letter from the FDA for cancer therapy - May 2nd, 2022 11:40 am
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA - May 2nd, 2022 11:00 am
CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022 - Apr 29th, 2022 8:01 pm
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022 - Apr 29th, 2022 12:45 pm
Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Apr 28th, 2022 7:02 pm
10 Biotech Stocks to Buy Today According to Kerr Neilson’s Platinum Asset Management - Apr 20th, 2022 6:25 pm
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States - Apr 14th, 2022 12:30 pm
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting - Apr 8th, 2022 5:10 pm
7 Biotech Stocks to Buy With Key Catalysts for April - Apr 5th, 2022 10:59 am
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event - Mar 29th, 2022 1:15 pm